Trial readouts and research news, one live feed.
Trial readouts, licensing deals, research findings and regulatory milestones — Newsfile's biotech wire and Newswise's science-news service, streaming beside the FDA and the health verticals of the commercial wires.
Trial-result announcements move stock prices and story budgets alike — alert on a molecule, an indication or "topline results" and the release reaches you within minutes of the wire.
Newswise's science-news service carries announcements from universities and research institutes — the discovery layer that feeds next year's pipeline stories.
The FDA's newsroom streams in our health vertical on the same subscription — approvals, holds and safety communications beside the company announcements they respond to.
The biotech feed is for life-science journalists, biopharma analysts and trade reporters who live between the lab and the market. The beat's defining events — a topline readout, a licensing deal, an FDA milestone — all arrive first as wire copy, often timed to market hours and worded by lawyers; PPN World puts the primary text in front of you the minute it publishes, with an AI summary that extracts the endpoint from the hedging. Company-focused reporters run entity alerts on their coverage universe; institutional communicators and IR teams track competitor readouts and regulator language in one view. The health vertical's agency feeds ride in the same $99/month subscription.
Dedicated biotech wires are only part of the picture — every general newswire we poll (PR Newswire, GlobeNewswire, Business Wire and the rest of the 80+) carries this vertical too, and saved searches catch those releases wherever they land.
Which biotech sources does PPN World monitor?+
How is this different from the health vertical?+
Can I alert on a specific drug or company?+
Own the biotech wire.
Every feed in this vertical — plus the other 400+ — deduplicated by story, with AI summaries and saved-search alerts. 14 days full access, card required, cancel anytime.